Artesunate

證據等級: L5

預測適應症: 10 個

Artesunate: From Malaria to Acne

One-Sentence Summary

Artesunate is a semisynthetic derivative of artemisinin, widely recognised as a frontline treatment for severe and uncomplicated malaria globally. The TxGNN model predicts it may be effective for Acne (disease) as its top-ranked new indication, yet no clinical trials or published literature were found to support this specific direction. Across all 10 predicted indications, every candidate sits at evidence level L5 (model prediction only), with diffuse cutaneous leishmaniasis (rank 6) standing out as the mechanistically best-supported candidate.

Quick Overview

Item	Content
Original Indication	Malaria (severe and uncomplicated)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	79.21%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Artesunate belongs to the artemisinin family of antimalarial compounds. Its canonical mechanism relies on an endoperoxide bridge that is cleaved by free iron derived from haem within parasite cells, generating a burst of reactive oxygen species (ROS) that cause lethal oxidative damage to the parasite. Beyond antiparasitic activity, artesunate has demonstrated broad anti-inflammatory properties in preclinical models, primarily through suppression of NF-κB signalling and its downstream cytokines (IL-1β, TNF-α, IL-6). In vitro data also suggest that artemisinin derivatives may exert direct antimicrobial activity via ROS-mediated mechanisms.

Acne vulgaris is a multifactorial inflammatory skin condition driven by sebaceous hyperactivity, follicular hyperkeratosis, colonisation by Cutibacterium acnes, and downstream inflammatory cytokine cascades. Artesunate's theoretical relevance rests on two pillars: (1) its NF-κB inhibitory activity could dampen the inflammatory component of acne lesions; and (2) artemisinin derivatives have demonstrated in vitro inhibitory activity against C. acnes, possibly through the same ROS mechanism that governs antiparasitic action.

However, the mechanistic link is indirect and the evidence base is very thin. Systemic anti-inflammatory effects may not translate to the sebaceous follicle microenvironment, and no artesunate-specific in vitro acne models have been published. This remains a hypothesis requiring bench-level validation before any clinical consideration.

Clinical Trial Evidence

Currently no related clinical trials registered for Artesunate in acne (disease).

Literature Evidence

Currently no related literature available for Artesunate in acne (disease).

Singapore Market Information

Artesunate holds no product registrations in Singapore. The drug is currently not marketed and no Health Sciences Authority (HSA) licence records are available for review.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal warning and contraindication data from the regulatory package insert were not available for this evaluation (classified as a blocking data gap). General safety considerations known from the antimalarial indication — including post-treatment haemolytic anaemia (reported with intravenous use) and hepatotoxicity signals — should be reviewed via WHO prequalification documentation or the originator's Summary of Product Characteristics before any repurposing study is designed.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications sit at L5, meaning none is supported by clinical trials or published literature at this time; acne (disease), while the highest-scored candidate, rests on an indirect and unvalidated mechanistic hypothesis, making any immediate clinical or regulatory pathway premature.

To proceed, the following is needed:

Fill critical data gaps first: Obtain MOA details from DrugBank API and download the package insert to complete the safety profile — both are currently blocking or high-severity gaps
In vitro validation for acne: Conduct C. acnes minimum inhibitory concentration (MIC) assays with artesunate and an NF-κB inhibition assay in a sebocyte inflammation model
Prioritise the higher-readiness indication: Consider redirecting initial efforts toward diffuse cutaneous leishmaniasis (rank 6), which carries the strongest mechanistic rationale (ROS sensitivity of Leishmania parallels malaria), an unmet medical need (high toxicity of existing therapies, frequent drug resistance in diffuse cutaneous type), and a large existing human safety dataset from malaria treatment
Dermatological pharmacokinetics: If the acne direction is retained, characterise skin penetration and local drug concentration achievable with feasible formulations (topical vs. systemic)
Singapore regulatory pathway: As Artesunate is not registered in Singapore, any repurposing programme would require a de novo HSA application; early pre-submission consultation is advisable
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.